It is hard to recall exactly where in my personal journey we left off. Lin was very ill and things took a backseat. We have also been writing for Health Union’s site maculardegeneration.net and what I wrote about what and for whom is blurring.
Lin tells me I never told you I was in line to be included in a clinical trial..maybe. I say I’m sure I did…I think.
Be that as it may, let me tell you, even if I have told you before, I am in line to be included in a clinical trial. Sort of anticlimactic after anticipating something for three and a half years, but better late than never. [Lin/Linda here: check out Sue’s pages The Waiting Game and The Waiting Game Continues.]
I had wanted stem cells. Someday I will get stem cells, but just not today. What I am in line to get is APL-2. APL-2 is a complement factor inhibitor. It is in phase 3 clinical trials for Apellis. It’s been granted fast track status by the FDA which means its development and review will be expedited to get the drug to patients as soon as possible.
I was not super excited about APL2. I have not been able to read the published journal article on the phase 2 research because it has not been published. Poster presentation of the data suggested a slowing of the lesion growth by between a third and a half. There was no comparable reduction in the rate of acuity loss.
It really did not seem to me that that dog would hunt. I was less than enthusiastic but my retinologist assured me he thought it was great stuff with lots of potential. Also, it was the only game in town and I had gotten tired waiting. I told them I would be interested.
What is it? APL-2 is a complement C3 inhibitor. It interferes with the chemical changes that eventually lead to the immune system attacking an “invader”. However, this is a good thing because AMD is an autoimmune disease and the “invader” that is being attacked in this incidence is the host himself.
I am keeping my name in for stem cells…for now. Once I am enrolled in the trial, I am no longer eligible for inclusion in any other research. Better the bird in hand. APL-2 is next up and my retinology team does not appear to have anything else to offer me.
Like I said, I am tired of waiting and feel the time is right for me. I have a steady income I no longer have to actually work for and some flex in my schedule where I do work. My eyes are not getting any better and I remain a “good” candidate, relatively free of other medical concerns. For me, it is time.
The new master plan if I get in the study? Lobby to get into – or maybe I may even had to lobby for – the study to see how stem cell RPE replacement works in eyes treated with APL-2. Then, generously volunteer for photoreceptors replacement research. Nobody ever said that was no method to my madness.
In the meantime, it is all a waiting game. I have discovered research is a maddening, not at all straightforward endeavor. They ask a series of tantalizing questions and they you won’t hear for months. What happens next in my personal story? Well, I do have some other pages coming your way…
Written June 20th, 2019